Evidence map›Paper›PMID 32764794›Full record

ArticlePloS one2020

Plasma biomarkers of the amyloid pathway are associated with geographic atrophy secondary to age-related macular degeneration.

Kameran Lashkari, Gianna C Teague, Ursula Beattie, Joanna Betts, Sanjay Kumar, Megan M McLaughlin, Francisco J López

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. AOxidative medicine and cellular longevity · 2022
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kameran LashkariSchepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
Gianna C TeagueSchepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0002-5715-3847
Ursula BeattieSchepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
Joanna BettsAlternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America.
Sanjay KumarAlternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America.
Megan M McLaughlinAlternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America.
Francisco J LópezAlternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America.
GlaxoSmithKline (United States) · USMassachusetts Eye and Ear Infirmary · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD), in which local inflammation and hyperactivity of the complement pathway have been implicated in its pathophysiology. This study explores whether any surrogate biomarkers are specifically associated with GA. Plasma from subjects with GA, intermediate dry AMD and non-AMD control were evaluated in 2 cohorts. Cohort 1 was assayed in a 320-analyte Luminex library. Statistical analysis was performed using non-parametric and parametric methods (Kruskal-Wallis, principal component analysis, partial least squares and multivariate analysis of variance (MANOVA) and univariate ANCOVAs). Bioinformatic analysis was conducted and identified connections to the amyloid pathway. Statistically significant biomarkers identified in Cohort 1 were then re-evaluated in Cohort 2 using individual ELISA and multiplexing. Of 320 analytes in Cohort 1, 273 were rendered measurable, of which 56 were identified as changing. Among these markers, 40 were identified in univariate ANCOVAs. Serum amyloid precursor protein (sAPP) was analyzed by a separate ELISA and included in further analyses. The 40 biomarkers, sAPP and amyloid-β (Aβ) (1-42) (included for comparison) were evaluated in Cohort 2. This resulted in 11 statistically significant biomarkers, including sAPP and Aβ(1-40), but not Aβ(1-42). Other biomarkers identified included serum proteases- tissue plasminogen activator, tumor-associated trypsinogen inhibitor, matrix metalloproteinases 7 and 9, and non-proteases- insulin-like growth factor binding protein 6, AXL receptor tyrosine kinase, omentin, pentraxin-3 and osteopontin. Findings suggest that there is a preferential processing of APP to Aβ(1-40) over Aβ(1-42), and a potential role for the carboxylase activity of the γ-secretase protein, which preferentially splices sAPPβ to Aβ(1-40). Other markers are associated with the breakdown and remodeling of the extracellular matrix, and loss of homeostasis, possibly within the photoreceptor-retinal pigment epithelium-choriocapillaris complex. These data suggest novel disease pathways associated with GA pathogenesis and could provide potential novel targets for treatment of GA.

Indexed as

AgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCohort StudiesComputational BiologyFemaleFundus OculiGeographic AtrophyHumansMacular DegenerationMaleMiddle AgedOptical ImagingRetinal Pigment EpitheliumSignal TransductionAmyloid beta-PeptidesBiomarkersPLAT protein, humanTissue Plasminogen Activator

Identifiers

PMID32764794
PMCPMC7413518
OpenAlexW3047684871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.